|
Sen. Terry Link
Filed: 3/7/2017
| | 10000SB0636sam002 | | LRB100 06838 SMS 22886 a |
|
|
1 | | AMENDMENT TO SENATE BILL 636
|
2 | | AMENDMENT NO. ______. Amend Senate Bill 636 by replacing |
3 | | everything after the enacting clause with the following:
|
4 | | "Section 5. The Pharmacy Practice Act is amended by |
5 | | changing Section 4 as follows:
|
6 | | (225 ILCS 85/4) (from Ch. 111, par. 4124)
|
7 | | (Section scheduled to be repealed on January 1, 2018)
|
8 | | Sec. 4. Exemptions. Nothing contained in any Section of |
9 | | this Act shall
apply
to, or in any manner interfere with:
|
10 | | (a) the lawful practice of any physician licensed to |
11 | | practice medicine in
all of its branches, dentist, podiatric |
12 | | physician,
veterinarian, or therapeutically or diagnostically |
13 | | certified optometrist within
the limits of
his or her license, |
14 | | or prevent him or her from
supplying to his
or her
bona fide |
15 | | patients
such drugs, medicines, or poisons as may seem to him |
16 | | appropriate;
|
|
| | 10000SB0636sam002 | - 2 - | LRB100 06838 SMS 22886 a |
|
|
1 | | (b) the sale of compressed gases;
|
2 | | (c) the sale of patent or proprietary medicines and |
3 | | household remedies
when sold in original and unbroken packages |
4 | | only, if such patent or
proprietary medicines and household |
5 | | remedies be properly and adequately
labeled as to content and |
6 | | usage and generally considered and accepted
as harmless and |
7 | | nonpoisonous when used according to the directions
on the |
8 | | label, and also do not contain opium or coca leaves, or any
|
9 | | compound, salt or derivative thereof, or any drug which, |
10 | | according
to the latest editions of the following authoritative |
11 | | pharmaceutical
treatises and standards, namely, The United |
12 | | States Pharmacopoeia/National
Formulary (USP/NF), the United |
13 | | States Dispensatory, and the Accepted
Dental Remedies of the |
14 | | Council of Dental Therapeutics of the American
Dental |
15 | | Association or any or either of them, in use on the effective
|
16 | | date of this Act, or according to the existing provisions of |
17 | | the Federal
Food, Drug, and Cosmetic Act and Regulations of the |
18 | | Department of Health
and Human Services, Food and Drug |
19 | | Administration, promulgated thereunder
now in effect, is |
20 | | designated, described or considered as a narcotic,
hypnotic, |
21 | | habit forming, dangerous, or poisonous drug;
|
22 | | (d) the sale of poultry and livestock remedies in original |
23 | | and unbroken
packages only, labeled for poultry and livestock |
24 | | medication;
|
25 | | (e) the sale of poisonous substances or mixture of |
26 | | poisonous substances,
in unbroken packages, for nonmedicinal |
|
| | 10000SB0636sam002 | - 3 - | LRB100 06838 SMS 22886 a |
|
|
1 | | use in the arts or industries
or for insecticide purposes; |
2 | | provided, they are properly and adequately
labeled as to |
3 | | content and such nonmedicinal usage, in conformity
with the |
4 | | provisions of all applicable federal, state and local laws
and |
5 | | regulations promulgated thereunder now in effect relating |
6 | | thereto
and governing the same, and those which are required |
7 | | under such applicable
laws and regulations to be labeled with |
8 | | the word "Poison", are also labeled
with the word "Poison" |
9 | | printed
thereon in prominent type and the name of a readily |
10 | | obtainable antidote
with directions for its administration;
|
11 | | (f) the delegation of limited prescriptive authority by a |
12 | | physician
licensed to
practice medicine in all its branches to |
13 | | a physician assistant
under Section 7.5 of the Physician |
14 | | Assistant Practice Act of 1987. This
delegated authority under |
15 | | Section 7.5 of the Physician Assistant Practice Act of 1987 |
16 | | may, but is not required to, include prescription of
controlled |
17 | | substances, as defined in Article II of the
Illinois Controlled |
18 | | Substances Act, in accordance with a written supervision |
19 | | agreement; and
|
20 | | (g) the delegation of prescriptive authority by a physician
|
21 | | licensed to practice medicine in all its branches or a licensed |
22 | | podiatric physician to an advanced practice
nurse in accordance |
23 | | with a written collaborative
agreement under Sections 65-35 and |
24 | | 65-40 of the Nurse Practice Act ; and .
|
25 | | (h) the sale or distribution of dialysate or devices |
26 | | necessary to perform home peritoneal renal dialysis for |
|
| | 10000SB0636sam002 | - 4 - | LRB100 06838 SMS 22886 a |
|
|
1 | | patients with end-stage renal disease, provided that all of the |
2 | | following conditions are met: |
3 | | (1) the dialysate, comprised of dextrose or |
4 | | icodextrin, or devices are approved or cleared by the |
5 | | federal Food and Drug Administration, as required by |
6 | | federal law; |
7 | | (2) the dialysate or devices are lawfully held by a |
8 | | manufacturer or the manufacturer's agent, which is |
9 | | properly registered with the Board as a manufacturer or |
10 | | wholesaler; |
11 | | (3) the dialysate or devices are held and delivered to |
12 | | the manufacturer or the manufacturer's agent in the |
13 | | original, sealed packaging from the manufacturing |
14 | | facility; |
15 | | (4) the dialysate or devices are delivered only upon |
16 | | receipt of a physician's prescription by a licensed |
17 | | pharmacy in which the prescription is processed in |
18 | | accordance with provisions set forth in this Act, and the |
19 | | transmittal of an order from the licensed pharmacy to the |
20 | | manufacturer or the manufacturer's agent; and |
21 | | (5) the manufacturer or the manufacturer's agent |
22 | | delivers the dialysate or devices directly to: (i) a |
23 | | patient with end-stage renal disease, or his or her |
24 | | designee, for the patient's self-administration of the |
25 | | dialysis therapy or (ii) a health care provider or |
26 | | institution for administration or delivery of the dialysis |
|
| | 10000SB0636sam002 | - 5 - | LRB100 06838 SMS 22886 a |
|
|
1 | | therapy to a patient with end-stage renal disease. |
2 | | This paragraph (h) does not include any other drugs for |
3 | | peritoneal dialysis, except dialysate, as described in item (1) |
4 | | of this paragraph (h). All records of sales and distribution of |
5 | | dialysate to patients made pursuant to this paragraph (h) must |
6 | | be retained in accordance with Section 18 of this Act. |
7 | | (Source: P.A. 98-214, eff. 8-9-13.)
|
8 | | Section 99. Effective date. This Act takes effect upon |
9 | | becoming law.".
|